<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF
1934 (AMENDMENT NO. 7)*
QUIPP, INC.
----------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK
----------------------------------------------------------------------
(Title of Class of Securities)
748802 10 5
------------------
(CUSIP Number)
KENNETH G. LANGONE
375 PARK AVENUE
NEW YORK, NEW YORK 10152
----------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
JULY 17, 1995
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP NO. 748802 10 5 SCHEDULE 13D PAGE 2 OF 4 PAGES
<TABLE>
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
KENNETH G. LANGONE ###-##-####
- ---------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / /
(B) / /
- ---------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
00
- ---------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or (e) / /
- ---------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES OF AMERICA
- ---------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 146,500 SHARES
SHARES ----------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY - 0 - SHARES
EACH ----------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 146,500 SHARES
WITH ----------------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- 0 - SHARES
- ---------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
146,500 SHARES
- ---------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ---------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.1%
- ---------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ---------------------------------------------------------------------------------------------------------------------------
SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE> 3
CUSIP NO. 748802 10 5 SCHEDULE 13D PAGE 3 OF 4 PAGES
This Amendment No. 7 amends and supplements Amendment No. 6 to
Schedule 13D (the "Schedule 13D") filed on behalf of Kenneth G. Langone,
successor-in-interest to North-South Investors II filed with the Commission on
November 16, 1989. Capitalized terms used herein and not otherwise defined
shall have the meaning ascribed to them in the Schedule 13D.
The purpose of this amendment is to amend Item 5 of the
Schedule 13D as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Kenneth G. Langone beneficially owns 146,500 shares of Quipp
common stock, constituting 9.1% of the total shares of Quipp common stock
outstanding. Such amount includes 45,400 shares owned by Invemed, a wholly
owned subsidiary of Invemed Securities, Inc., which is 81% owned by Mr.
Langone, and excludes warrants to purchase 42,500 shares of Quipp common stock
which were held by Invemed prior to their expiration on August 18, 1991.
Kenneth G. Langone has sole power to vote or to direct the
vote, and sole power to dispose or direct the disposition, of the reported
shares.
On July 17, 1995, Invemed sold 16,500 shares of Quipp common
stock for $13.70 per share; on July 18, 1995, Invemed sold 1,500 shares of
Quipp common stock for $13.50 per share; and on August 1, 1995, Invemed sold
1,917 shares of Quipp common stock for $14 per share, 1,752 shares of Quipp
common stock for $14.25 per share and 906 shares of Quipp common stock for
$13.75 per share.
<PAGE> 4
CUSIP NO. 748802 10 5 SCHEDULE 13D PAGE 4 OF 4 PAGES
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
October 24, 1995
------------------------
(Date)
/s/ Kenneth G. Langone
------------------------
(Signature)
Kenneth G. Langone
------------------------
(Name/Title)
